// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Late Breaking Abstract - The humanistic burden of asthma patients uncontrolled on ICS-LABA: a systematic literature review

Alexandrosz Czira - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

CAPTAIN: Effects of age on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA

Louis-Philippe Boulet - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Fluticasone furoate

Effect of triple therapy with extra-fine BDP/FF/GB pMDI during seasonal peaks of asthma exacerbations. A post-hoc analysis of the TRIMARAN and TRIGGER studies

Alberto Papi - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Salbutamol

Clinical indicators of treatment response to Mepolizumab at 12 weeks

Yik Lam Pang - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

Real world outcomes of Mepolizumab for severe asthma in Wales a retrospective analysis

Andrew Harries - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy

Omer Elneima - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

Late Breaking Abstract - Phenotyping Mepolizumab EXacerbations in severe eosinophilic asthma (MEX

Pamela Jane McDowell - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Angela Moran - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Benralizumab

Severe asthma outcomes over 18-months treatment with mepolizumab, and comorbidities in non-responders

Lynn Elsey - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma

Joanne Kavanagh - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Benralizumab

Characterising individual response to mepolizumab treatment

David Jackson - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Mepolizumab

Efficacy of as-needed budesonide/formoterol in mild asthma: pooled analysis of SYGMA 1 and 2

Eric D. Bateman - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

budesonide + formoterol fuma

Characterising asthma exacerbations in the CAPTAIN trial

Laurie Lee - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study

Wilhelmine Meeraus - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Tiotropium bromide

CAPTAIN: Effects of smoking status on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA

Alberto Papi - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Fluticasone furoate

Late Breaking Abstract - Cardio-selective beta1-blockers in asthma: a search of the World Health Organization Global Database of Individual Case Safety reports (VigiBase

Miriam Bennett - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata

Chris Compton - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

fluticasone furoate/umeclidinium/vilanterol

Characterising patients with COPD by baseline short-acting ß2-agonist (SABA use: a post hoc analysis of the EMAX trial

Edward Kerwin - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI at two ICS dose levels in the ETHOS trial: a subgroup analysis

Klaus F. Rabe - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

budesonide + formoterol fuma

Ensifentrine added on to tiotropium significantly improves lung function, symptoms and QoL in symptomatic COPD patients regardless of baseline reversibility

Kathleen Rickard - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Tiotropium bromide

Copyright © 2026. QuantiNova All rights reserved